Dicot (DICOT) Investor update summary

Rights issue progress and shareholder commitments

• Indications of interest from major shareholders total approximately SEK 15.6 million, about 7.4% of the rights issue.

• Previous subscription commitments from shareholders, board, and executives amount to SEK 33.3 million, or 15.9% of the rights issue.

• Underwriting commitments from institutional investors total SEK 150.5 million, covering 71.6% of the rights issue.

• The rights issue is guaranteed up to 80%, ensuring sufficient funds for the planned phase 2b study.

Investor communication and regulatory compliance

• A company presentation and Q&A session regarding the rights issue will be held via Zoom on May 27, 2026.

• An EU Follow-on Prospectus for the rights issue was approved by the Finansinspektionen on May 19, 2026.

• Corpura Fondkommission AB acts as sole global coordinator and bookrunner; Advokatfirman Lindahl KB is legal adviser.

• The offering is only available in Sweden and is not open to investors in restricted jurisdictions.

Forward-looking statements and company overview

• Forward-looking statements reflect expectations for future financial and operational development, subject to risks and uncertainties.

• LIB-01 is being developed to treat erectile dysfunction and premature ejaculation, targeting a USD 8 billion market.

• The business model includes seeking industrial and financial partnerships during clinical development.

• Listed on Nasdaq First North with about 16,750 shareholders.